New York, New York–(Newsfile Corp. – April 6, 2026) – Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited (NASDAQ:IMMP) (“Immutep Limited”) concerning potential violations of the federal securities laws.
On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was “on track for the first quarter of CY2026” and cited “strong operational progress” for the trial. The filing contained no reference to negative efficacy signals, enrollment difficulties, or data trends that might compromise the trial’s primary endpoints. Six weeks later, on March 13, 2026, the IDMC announced the interim futility analysis showed the drug was unlikely to succeed and recommended stopping the study. TACTI-004 was Immutep’s lead oncology asset.
The January 30 filing framed the futility analysis as a forward milestone still…
Investment fraud targets the human desire for financial growth by promising high returns with “low to no risk.”
- Ponzi Schemes: Named after Charles Ponzi, these schemes pay “returns” to earlier investors using the capital brought in by newer investors. There is no actual underlying business; the system collapses when new recruitment slows down.
- Pyramid Schemes: Similar to Ponzi schemes, but participants are usually required to sell a product or service. The primary “profit” comes from the recruitment fees of new members rather than actual product sales.
- Pump and Dump: Fraudsters spread false, positive rumors about a cheap stock (the “pump”) to drive up the price. Once the price peaks, they sell their shares (the “dump”), leaving other investors with worthless stock.